14 completed, 6 recruiting, 5 active not recruiting, 5 terminated. 37 Phase 3, 12 Phase 2.
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-04 | 2026-09-28 |
| Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer Comprehensive Geriatric Assessment - Hepatobiliary Cancer, Pancreatic Cancer | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 526 | 2025-09-01 | 2025-05-31 |
| Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) neoadjuvant chemotherapy, curative surgery - Gall Bladder Carcinoma | Phase 3 | Recruiting | Rajiv Gandhi Cancer Institute & Research Center, India | 114 | 2025-01-01 | 2025-04-16 |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Zanidatamab, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 286 | 2024-07-19 | 2026-10-28 |
| Radiation Therapy in Unresectable Gall Bladder Cancer Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin) - Gall Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Tata Memorial Centre | 249 | 2024-03-07 | 2025-04-11 |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer | Phase 3 | Active not recruiting | AstraZeneca | 760 | 2023-12-04 | 2026-10-16 |
| Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction Primary percutaneous stenting (PPS), Endoscopic biliary drainage - Cholangiocarcinoma Non-resectable, Gall Bladder Cancer | Phase 3 | Enrolling by invitation | Erasmus Medical Center | 148 | 2023-08-09 | 2024-11-04 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Compass Therapeutics | 168 | 2023-01-09 | 2026-09-02 |
| Addition of Everolimus to Standard of Care in Carcinoma Gallbladder Everolimus 10 mg, Standard of care - Gallbladder Cancer | Phase 2 / Phase 3 | Unknown | Banaras Hindu University | 56 | 2022-11-01 | 2024-08-13 |
| Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy - Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 186 | 2021-02-24 | 2026-10-19 |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study Pembrolizumab, Gemcitabine, Cisplatin - Biliary Tract Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 158 | 2020-07-10 | 2026-04-15 |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) Pembrolizumab, Gemcitabine, Cisplatin - Biliary Tract Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1069 | 2019-09-24 | 2026-03-24 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 309 | 2019-09-20 | 2023-11-14 |
| Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Capecitabine, Cisplatin, Gemcitabine - Stage I Gallbladder Cancer AJCC v8, Stage II Gallbladder Cancer AJCC v8 | Phase 3 | Withdrawn | Emory University | 2019-04-03 | 2020-06-05 | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8 | Phase 3 | Completed | SWOG Cancer Research Network | 452 | 2019-02-07 | 2026-01-12 |
| Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Gemcitabine, Capecitabine - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 460 | 2018-12-15 | 2018-12-19 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Gemcitabine, Cisplatin, Chemoradiation - Gall Bladder Cancers | Phase 2 / Phase 3 | Active not recruiting | Tata Memorial Hospital | 124 | 2016-09-06 | 2025-03-13 |
Showing 20 of 37. Sign in to see all of them.
Bile Duct Neoplasms (15) · Cholangiocarcinoma (13) · Biliary Tract Neoplasms (10) · Liver Neoplasms (6) · Pancreatic Neoplasms (6) · Carcinoma, Hepatocellular (5) · Colonic Neoplasms (4) · Neoplasms (4) · Stomach Neoplasms (4) · Esophageal Neoplasms (3) · Lung Neoplasms (3) · Prostatic Neoplasms (3) · Appendiceal Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2)
Biliary Tract Diseases (37) · Digestive System Diseases (37) · Digestive System Neoplasms (37) · Gallbladder Diseases (37) · Neoplasms by Site (37) · Neoplasms (33) · Biliary Tract Neoplasms (27) · Adenocarcinoma (18) · Carcinoma (18) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (18) · Bile Duct Diseases (15) · Liver Diseases (9) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6)
Gemcitabine (18) · Cisplatin (15) · Capecitabine (8) · Oxaliplatin (5) · Chemotherapy, Adjuvant (3) · Leucovorin (3) · durvalumab (3) · pembrolizumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · 130-nm albumin-bound paclitaxel (2) · Chemoradiotherapy (2) · Dihematoporphyrin Ether (2) · Fluorouracil (2) · Platinum (2) · Watchful Waiting (2)
AstraZeneca (2) · Merck Sharp & Dohme LLC (2) · NCIC Clinical Trials Group (2) · University College, London (2) · ASLAN Pharmaceuticals (1) · All India Institute of Medical Sciences (1) · Assistance Publique - Hôpitaux de Paris (1) · Auron Healthcare GmbH (1) · Banaras Hindu University (1) · Cancer Research UK (1) · Compass Therapeutics (1) · ECOG-ACRIN Cancer Research Group (1) · EMD Serono Research & Development Institute, Inc. (1) · Emory University (1) · Erasmus Medical Center (1)
United States (15) · United Kingdom (12) · China (10) · France (9) · Canada (8) · Germany (8) · India (8) · Italy (7) · Spain (7) · Australia (6) · Japan (6) · South Korea (6) · Taiwan (6) · Belgium (5) · Brazil (5)
Afshin Dowlati, MD (1) · Bruno Chauffert (1) · Clive Stubbs (1) · Cynthia Sirard, MD (1) · Eric K Rowinsky, MD (1) · Eveline Boucher, MD (1) · Ghassan Abou-Alfa, MD (1) · Henning Wege (1) · James Farrell, MD (1) · Jennifer Knox, MD (1) · Joachim Drevs, PD Dr. Med (1) · John A. Bridgewater (1) · Juan Valle, Prof (1)
PMID 38661512, PMID 42176183, PMID 16849762, PMID 20375404, PMID 22480131, PMID 25241229, PMID 26228433, PMID 27020837, PMID 31253621, PMID 32461347, PMID 33798493, PMID 34515993, PMID 37075781, PMID 38861293, PMID 38875119, PMID 39206260, PMID 39671534, PMID 40154623, PMID 40268484, PMID 40346549, PMID 41887529
2023 (3), 2019 (2), K23CA115908 (1), U10CA180820 (1), U10CA180888 (1)